Relenza, the new flu treatment controversially excluded from the NHS because
a panel decided it was not cost-effective, can cause breathing difficulties in
patients with asthma. Glaxo Wellcome, which makes the drug, warned doctors of
the danger last week. The company says the number of people who have suffered
breathing difficulties after taking the drug is tiny, and that the warning is
simply a precaution. But the news is unfortunate, given that flu patients with
chronic lung disease are among the ones most likely to benefit from effective
influenza treatments.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features

Life
Fossil fruits show flowering plants flourished in time of dinosaurs
News

Environment
Can home batteries help save the climate and save you money?
News

ÎçÒ¹¸£Àû1000¼¯ºÏ
We’ve uncovered a master gene that switches on human development
News

Environment
The race to understand how and when Thwaites glacier will collapse
Features
Popular articles
Trending New Scientist articles
1
Woman with Alzheimer's starts conversing again after taking psilocybin
2
If you aren't terrified by this heatwave, you should be
3
The race to understand how and when Thwaites glacier will collapse
4
Lost books by ancient philosophers recovered from 'unreadable' scrolls
5
Our verdict on The Selfish Gene: An unpopular piece of popular science
6
We’ve uncovered a master gene that switches on human development
7
The best sci-fi novel in 2026 so far – plus 6 other great reads
8
Screwworm could be the first species targeted by an 'extinction drive'
9
How menopause radically changes the brain – and what happens after
10
Faecal transplant makes the brains of old mice act young again